
LCTX Stock Forecast & Price Target
LCTX Analyst Ratings
Bulls say
Lineage Cell Therapeutics is positioned for success with its COR1 program, utilizing its proprietary AlloSCOPE platform and leveraging ophthalmology and cell manufacturing expertise to achieve consistent, large-scale production of off-the-shelf allogeneic corneal endothelial cells. With COR1 addressing the current deficiencies of donor-derived CEnCs, Lineage can potentially capture a significant portion of the corneal transplant market, generating strong value for the stock. However, as with any biotech company, there are inherent risks in clinical/regulatory, partnership and financial, commercial, legal and intellectual property, and market share, which should be carefully monitored by investors.
Bears say
Lineage Cell Therapeutics is facing potential scalability and stability issues with its cell therapies due to its reliance on the AlloSCOPE platform and a single pluripotent cell line, and potential quality and safety concerns with its off-the-shelf strategy. While OpRegen shows initial promise, the company's reliance on partnerships and external validation, as well as its limited cash reserves, may hinder its potential for long-term success.
This aggregate rating is based on analysts' research of Lineage Cell Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.
LCTX Analyst Forecast & Price Prediction
Start investing in LCTX
Order type
Buy in
Order amount
Est. shares
0 shares